ArticleBlood advances2026
Digital spatial profiling uncovers transcriptomic features of distinct plasma cell-like phenotypes in diffuse large B-cell lymphoma.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Multi-Omics Framework Reveals Tumor Heterogeneity and Predicts Therapeutic Targets in Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractDiffuse large B-cell lymphoma (DLBCL) exhibits marked heterogeneity, complicating treatment and prognosis. The role of plasma cell-like phenotypes in DLBCL remains underexplored. Using spatially resolved transcriptomics, we profiled 4 distinct plasma cell-like phenotypes in DLBCL based on CD20, HLA-DRA, and PR domain zinc finger protein 1 (PRDM1) markers: CD20+HLA-DRA+ PRDM1-, CD20+ HLA-DRA+ PRDM1+, CD20+ HLA-DRA-PRDM1-, and CD20+ HLA-DRA-PRDM1+. The CD20+ HLA-DRA+ PRDM1- phenotype (nonplasma cell-like phenotype) had better prognosis; the other 3 phenotypes (plasma cell-like phenotypes) had worse prognosis. Patients with >30% plasma cell-like phenotype cells were classified as DLBCL plasma cell-like phenotype predominant (DLBCLPCPP), and those with ≤30% as DLBCL plasma cell-like phenotype deficient (DLBCLPCPD). Plasma cell-like phenotype cells correlated with reduced proliferation, impaired immune function, and enhanced tumor microenvironment remodeling. DLBCLPCPP had lower Ki-67 index of ≥85% (29.6% vs 53.9%, P = .0198), similar first-line response (92.6% vs 92.6%, P = 1.00) but a higher rate of disease progression within 12 months (25.9% vs 3.7%, P = .0238) and more B2M alterations (22.2% vs 3.7%, P = .0509) compared with DLBCLPCPD. Transcriptomic revealed of plasma cell-like phenotype cells to plasmablastic lymphoma. Using phenotype-associated genes, we constructed a random forest model to predict bortezomib response. High plasma cell-like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) plus bortezomib (RB-CHOP), low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell-like phenotypes in DLBCL, offering new insights for prognostic relevance and individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.